Physician profile
Cynthia Holt Bedell
NPI 1306976436
$168,194.03
in general payments reported to CMS, 2019-2025
45 companies · $2,104 in 2025
The $2,104 reported for 2025 was more than what 94% of Adult Health (Nurse Practitioner) providers received nationally (typical 2025 total: $182).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $60K · 2022: $57K · 2023: $33K · 2024: $16K · 2025: $2,104.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $32K · Travel and Lodging: $11K · Food and Beverage: $4,172 · Consulting Fee: $2,525 · Long Term Medical Supply Or Device Loan: $1,097.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $31,935.00 |
| Travel and Lodging | $11,192.24 |
| Food and Beverage | $4,172.43 |
| Consulting Fee | $2,525.00 |
| Long Term Medical Supply Or Device Loan | $1,096.70 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Seagen INC. | $85,003.94 | 2021-2023 | Tukysa |
| Astrazeneca Pharmaceuticals Lp | $41,078.30 | 2021-2025 | Enhertu, Imfinzi |
| Puma Biotechnology, INC. | $21,291.87 | 2021-2025 | Nerlynx |
| Daiichi Sankyo INC. | $12,608.77 | 2021-2025 | Enhertu |
| Genentech USA, INC. | $3,820.59 | 2021-2025 | Itovebi, Herceptin, Phesgo |
| Novartis Pharmaceuticals Corporation | $1,289.18 | 2022-2025 | |
| Incyte Corporation | $597.81 | 2021-2025 | Monjuvi, Jakafi, Niktimvo |
| Stemline Therapeutics INC. | $274.51 | 2023-2025 | Orserdu |
| Kite Pharma, INC. | $193.19 | 2021-2023 | |
| Genzyme Corporation | $164.57 | 2021-2024 | |
| Rigel Pharmaceuticals, INC. | $158.49 | 2021-2024 | Tavalisse, Rezlidhia |
| Mirati Therapeutics, INC. | $157.86 | 2023-2024 | Krazati |
| Lilly USA, LLC | $122.94 | 2023-2025 | Verzenio, Jaypirca |
| Abbvie INC. | $116.71 | 2022-2025 | |
| Glaxosmithkline, LLC. | $97.69 | 2021-2022 |
Show all 45 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Cynthia Bedell listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.